目录产品 » 抗体产品 » 一抗 » MonoRab™ SARS-CoV-2 Neutralizing Antibody (BS-R2B17), mAb, Rabbit

MonoRab™ SARS-CoV-2 Neutralizing Antibody (BS-R2B17), MAb, Rabbit

ELISA binding of MonoRab^TM SARS-CoV-2 Neutralizing Antibody (BS-R2B17), mAb, Rabbit (GenScript, A02052) with recombinant SARS-CoV-2 Spike Protein S1 RBD(GenScript, Z03483) and SARS-CoV RBD .

MonoRab™ SARS-CoV-2 Neutralizing Antibody (BS-R2B17), mAb, Rabbit (GenScript, A02052) blocks SARS-CoV-2 Omicron RBD binding with Human ACE2 recombinant protein by sVNT.

SARS-CoV-2 S-RBD Omicron/B.1.1.529 (GenScript, Z03728)
MonoRab™ SARS-CoV-2 Neutralizing Antibody (BS-R2B17), mAb, Rabbit dilution start from 10 µg/ml.

Pseudovirus Neutralization Test of SARS-CoV-2 pseudovirus–hACE2 interaction with MonoRab™ SARS-CoV-2 Neutralizing Antibody (BS-R2B17), mAb, Rabbit (GenScript, A02052).

Control: HEK293/ACE2 cells were infected with SARS-CoV-2 pseudovirus
SARS-CoV-2 Pseudovirus Neutralization Assay kit_Luc reporter (GenScript, L02087A)
SARS-CoV-2 B.1.617.2 (Delta) Pseudovirus Neutralization Assay kit _Luc reporter (GenScript, L02087V)
SARS-CoV-2 B.1.1.529 (Omicron) Pseudovirus Neutralization Assay kit _Luc reporter (GenScript, L02087-027)

MonoRab™ SARS-CoV-2 Neutralizing Antibody (BS-R2B17), mAb, Rabbit (GenScript, A02052) dilutions start from 40 µg/ml.

Dose-response curve of MonoRab™ SARS-CoV-2 Neutralizing Antibody (BS-R2B17), mAb, Rabbit (GenScript, A02052) on SARS-CoV-2 Multiplex sVNT.

The final concentration of RBD recombinant proteins were 60 ng/mL. MonoRab™ SARS-CoV-2 Neutralizing Antibody (BS-R2B17), mAb, Rabbit (GenScript, A02052) dilutions started from 10 µg/mL.
MonoRab™ SARS-CoV-2 Neutralizing Antibody (BS-R2B17), mAb, Rabbit (GenScript, A02052) can block the binding of SARS-CoV-2 omicron variant XBB sublineage and BQ.1.1 sublineage to Human ACE2.

MonoRab™ SARS-CoV-2 Neutralizing Antibody (BS-R2B17), mAb, Rabbit

The product is specific for SARS-CoV-2 Spike Protein S1 subunit and its RBD domain. The product can recognize and neutralize Wild-Type SARS-CoV-2 and Variants of Concern (VOC) including Alpha, Beta, Delta, and Omicron. Reactivity with Gamma variant has not been tested.

产品编号	A02052
规格	100 μg 1 mg 大单询价
数量
价格	￥2800


联系我们

产品概述

Specificity	The product is specific for SARS-CoV-2 Spike Protein S1 subunit and its RBD domain. The product can recognize and neutralize Wild-Type SARS-CoV-2 and Variants of Concern (VOC) including Alpha, Beta, Delta, and Omicron. Reactivity with Gamma variant has not been tested.
Host Species	Rabbit
Immunogen	Recombinant SARS-CoV-2 Spike protein fragment
Conjugate	Unconjugated

应用指导

Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product.

Application	Recommended Usage
ELISA	0.01-0.1 µg/ml
Flow Cytometry	10 µg/ml
Surrogate Virus Neutralization Test (sVNT)	0.2-1 µg/ml

产品属性

Form	Liquid
Storage Buffer	0.2 μm filtered solution in PBS, pH 7.4.
Concentration	1 mg/ml
Storage Instructions	Store at -20°C. This product is stable for 1 year upon receipt, when handled and stored as instructed. Avoid repeated freezing and thawing cycles.
Purification	Protein A affinity column
Isotype	Rabbit IgG
Clonality	Monoclonal
Clone ID	BS-R2B17
Note	GenScript can customize this product per customer's request including product size, buffer components, etc.

图例

ELISA binding of MonoRab^TM SARS-CoV-2 Neutralizing Antibody (BS-R2B17), mAb, Rabbit (GenScript, A02052) with recombinant SARS-CoV-2 Spike Protein S1 RBD(GenScript, Z03483) and SARS-CoV RBD .

技术背景

Target Background	SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2), also known as 2019-nCoV, is a positive-sense single-stranded RNA virus. It caused coronavirus disease 2019 (COVID-19). SARS-CoV-2 contains glycosylated spike (S) protein, which is composed of S1 subunit and S2 subunit. The S1 contains a receptor-binding domain (RBD) that can bind to ACE2 receptor on target cells.
Synonyms	2019-nCoV Neutralizing Antibody, mAb, Rabbit

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.